Nektaria Andronikou

Nektaria Andronikou joined Life Technologies in 2010 and is currently working with the transfection team on the development of new delivery methods targeting relevant cellular models that will enable the use of exciting new technologies. She received a Bachelor of Science in Biochemistry with a minor in Cellular and Molecular Biology from UCSD.  She began her professional career at ISIS Pharmaceuticals, as a research associate for the Cardiovascular Drug Discovery program, screening numerous pre-clinical targets that led to the discovery of the now FDA approved antisense drug, Kynamro.